Sign In
to Vote &
Create Storyboards.
 
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, has announced that the five-year follow-up of patients with high-risk malignancies from its Phase I/II clinical study confirms long-term safety and efficacy of ATIR(TM) over a broad dose range. ATIR(TM) is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for patients who do not have a standard of care stem cell donor av...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard